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To investigate the expression ofMTIFgene in hepatocellular carcinoma tissue and the growth sup-
pression effect ofexogenous introduction ofMTIF gene on liver cell line HepG2 and to explore the
potential application of MTIF gene in gene therapy of tumor Eukaryotic expression vector of
pCMV-MTIFplasmid was introduced into HepG2 line which expressed no MTIFprotein originally
with lipofectamine transfection method. The cell growth curve, soft agar colonyformation rate and
tumorigenicity in SCIDmice wereexaminedtodemonstrate thegrowthsuppression effectofexogenous
MTIFgene on HepG2 cell line .TheMTIFmRNA andMTJFprotein werealso detected in 60pairs of
surgical specimens ofhepatocellular carcinoma by in situ hybridization and immunohistochemistry.
The transfectedHepG2 celllinegrewmoreslowly than controlHepG2 as shown bycellgrowthcurves,
the softagarcolonyformation rate (3.8percentvs. 7.4percent, p < .01)andthe average growth rate of
tumor in SCID mice (30.9 ± 6.9 vs. 70.3 ± 5.6, p < .01) .The expression level ofMTJF mRNA and
protein significantly increasedinparacancerous tissue, normaltissue than in cancertissues (75percent,
70 percent vs. 16.7percent by ISH and 66.7percent, 60 percent vs. 10 percent by IHC, p < .01).
ExogenousMTIFgene shows thestrong effectofgrowth inhibition onHepG2 cellline. In the livercancer
tissue, MTIFshowsdown-regulatedexpression thatsupports the inhibitedfunction ofMTIFin cancer
growth andsuggests MTIFmay have an important role in gene therapy ofhepatocellularcarcinoma.
INTRODUCTION
Hepatocellular carcinoma (HCC)d is
one ofthe most common malignant tumors
in China, especially Qidong, a HCC high-
risk area. Its pathogenesis and develop-
ment are closely related with some of
proto-oncogenes and their products [1].
MT1F (BC027262) is known as a member
ofmetallothionein family characterized by
rapid and transient expression in response
to stimulation, modulating gene transcrip-
tion positively or negatively depending on
the cell types andplaying an importantrole
in the cell growth [1, 2]. But its relation-
ship with HCC is not well understood so
far. In order to evaluate the growth inhibi-
tion of MT1F on HepG2 and analyze the
expression of MT1F in HCC tissue, the
relationship between MT1F and hepatocel-
lular carcinoma is explored by the methods
of gene transfection, tumorigenicity in
c To whom all correspondence should be addressed: Lu DongDong, Ph.D., associate-pro-
fessor, The College of Life Science, Nanjing Normal University, Nanjing (210097), E-Mail:
Ludondon88@163.com
dAbbreviadons: CMV, cytomegalovirus; DAB, diaminobenzidine; HCC, Hepatocellular carcinoma;
MT1 F, Metallothionein-1 F; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.
5556 Lu etal: Metallothionein-1Fgene and hepatocellular carcinoma
severe combined immunodeficient (SCID)
mice and in situ hybridization, immunohis-
tochemistry, etc.
MATERIALS AND METHODS
Cell lines and tissues
Human hepatoma cell lines HepG2
was obtained from Shanghai Cell Research
Institute, These cells were cultured with
Dulbecco'sModifiedEaglemedium(DMEM)
supplemented with 10 percent heat-inacti-
vated fetal bovine serum (Sigma, United
States) at 37°C 5 percent CO2 incubator
unless otherwise noted.
Sixty pairs ofHCC and adjacent non-
tumor counterparts were obtained at time
of surgical resection from Qidong Liver
Cancer Institute, twenty normal human
liver tissues adjacent to hepatic metastatic
tumors of colon cancer were obtained at
the time of surgery and served as controls.
There were fixed in 40 mlfl neutral forma-
lin with 1/1000 diethyl pyrocarbonate
(DEPC, Sigma Chemical Company, United
States) embedded in paraffin, and the sec-
tions were cut in 5 im.
Eukaryotic expression vectorofpCMV-
MT1Fplasmid
The plasmid was constructed by us.
The final construct contains the neogene
(5.5 kb fragment) driven by the respiratory
syncytial virus (RSV) promoter and the
MT1F gene driven by the human
cytomegalovirus (CMV) promoter. The
plasmid was confirmed by amplification,
purification and tested by endonuclease
cutting.
Gene transfection
The eukaryotic expression vector of
pCMV-MTIF plasmid was transfected to
human HepG2 cell line by the lipofecta-
mine (Gibco Company, United States)
according to the manufacturer's instruc-
tions. After transfection, the cells were
trypsinized and reseeded at 1:2 ratio for
selection culture with G418 at 600 mg/l.
Four weeks later, the resistant colonies
were formed.
Detection of transfected cell neogene
with polymerase chain reaction
Extracting the cell DNA followed by
performingpolymerase chainreaction (PCR)
to amplify 327 bp of neogene with primer
1 (5'-ACAAGATGGATTGCACGCAGG-
3') and primer 2 (5-TTCTCGGCAGGAG-
CAAGGTGAG-3'). The cycling procedure
was denatured at 95°C for 1 min, annealed
at 55°C for 1.5 min, extended at 72°C for 1
min, and after 30 cycles, lengthened at
72°C for 5 min, The untransfected HepG2
cell line was used as a negative control.
Westemblotandimmunocytochemistry
TheM7TlFpolyclonalantibodyprepared
by us: The cDNA of MT1F was amplified
into prokaryatic expression vector and
transformed into BL21 for expression. By
Niaffinity Chromatography, the product
was identified to be a single component by
SDS-PAGE. The rabbits were immunized
withpurified product. Western blot analyz-
ing showed high titer rabbit anti-human
MT1F polyclonal antibody [3].
Cells (3 x 105) were harvested and
dissolved by the addition of sodium dode-
cyl sulfate (SDS)-containing lysis buffer.
The lysate was used for SDS-polyacry-
lamide gel electophoresis on a 7.5 percent
gel. The proteins were electrophoretically
transferred from the gel to NC membrane.
The transferred membrane was treated
with polycolonal antibody against MT1F
protein (1:200). Followed by detection
with peroxidase-labeled goat anti-rabbit
(1:1000, Dako, United States). The result-
ing complexes were detected with the ECL
reagent (Amersham Company, United
Kingdom) according to the manufacturer's
instructions. TheMT1Fprotein was detectedLu etal: Metallothionein-1Fgene and hepatocellular carcinoma 57
by immunocytochemistry. The untransfected
HepG2 cell line was used as a negative
control.
Detection of biological features in
transfected cells
Growth curve assays Cells (1 x 105)
were seeded in each well ofa24-well plate
and were allowed to grow for varying peri-
ods, The trypsinized cells were counted by
cell counter plate, The growth assays were
madebycounting in triplicate onevery other
day ofculture for up to 7 days followed by
constructing the cell growth curves.
Soft agar culture: The anchorage inde-
pendent growth was examined by seeding
1000 cells in 0.3 percent agar medium into
60 mm plates previously lined with 0.5
percent agar medium, The plates (in tripli-
cate and repeated twice) were cultured at
37°C, 5 percent CO2 incubator for 14 days.
The average number of colony formation
(any colony containing more than 50 cells
was counted as a colony) and the colony
formation rate (the number ofcolonies/the
number ofseeded cells) were calculated.
Tumorigenicity in SCID mice Two
groups were divided randomly. The exper-
imental group that consisted of six mice
was used for hepG2 cells with transfected
MT1F injection. The control group of five
mice was used for hepG2 cells without
transfected MT1F injection. Trypsinized
cells (5 x 106) were injected into the sub-
cutaneous sites on the shoulders of SCID
mice. Animals were inspected at regular
intervals for the appearance of visible
tumors to measure the time offirst appear-
ance. Thirty days later, the mice were sac-
rificed and the tumors were carefully
removed by blunt dissection. The tumors
were weighed and their average growth
rates were measures as mg/day.
MT1Fin situ hybridization
The expression ofMT1F was detected
by digoxigenin-labeled gene probe. The
human breast tissue and the mouse brain
tissue were used as the positive control.
Either the sections detected with incuba-
tion solution instead of the probe or the
sections detected with ribonucleases
(Rnase) (10mg/ml) before MT1Fdetection
was designed for the negative control. The
positive expression showed the brown
staining signal in the cytoplasm.
Immunohistochemistry: MT1Fwasana-
lyzed by using MT1F rabbit polyclonal
antiserum with the SABC methodfollowing
treatment with3,3'diaminobenzidine (DAB)
staining. The human breast tissue and the
mouse brain tissue were used as the posi-
tive control. Negative control was designed
using phosphate-buffered saline (PBS)
instead of MT1F rabbit polyclonal anti-
serum in detection. The positive expression
showed the brown staining signal in nuclei.
STATISTICAL ANALYSIS
The data were statistically analyzed
using Student's t test and the difference of
results was analyzed by U test and T test.
RESULTS
Identification ofplasmid
The eukaryotic expression vector of
PCMV-MTIF plasmid was tested by PCR
amplification. purification and restriction
endonuclease and confirmed to be consis-
tent with the plasmid map. With single
digestion of EcoRI, a 6.1 kb band was
obtained which represents the whole length
of the plasmid DNA. With double diges-
tion of EcoRI combining with Xho I, both
5.5 kb and 0.673 kb bands were obtained
which represented the fragment ofthe vec-
tor and MT1F gene fragment respectively.
Gene transfection
HepG2 was transfected with pCMV-
MT1F plasmid by lipofectamine transfec-
tion method. Four weeks after G418 selec-Lu et al: Metallothionein-1Fgene and hepatocellular carcinoma
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Figure 1. Western blot analysis of MT1F, (A) HepG2 was transfected with pCMV plasmid
by lipofectamine transfection; (B) HepG2 was transfected with pCMV-MT1 F plasmid
by lipofectamine transfection
Figure 2. The transfected HepG2 was positively brown stained in the cytoplasmic or
nucleus (A) compared to the negative staining for control (B).
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C
a
ci)
E
a3
c:
40
35
30
25
20
15
10
5
0
58Lu et al: Metallothionein-1F gene and hepatocellular carcinoma 59
IM~~~~~~~
Figure 4. Immunohistochemical staining for MT1F; (A) For HCC, cytoplasmic and
nuclear staining was dominant whereas membrane staining was rare, showing
brown DAB x 200; (B) Para-cancerous livertissue showed membrane or cytoplasmic
staining like normal livertissue, showing brown DAB x 200; (C) In normal livertissue,
the staining was mainly positive on the cellular membrane or cytoplasmic staining,
showing brown DAB x 200.
tion culture, the resistant colonies were
formed. PCR Indicated that 327 bp ofneo-
gene was shown in transfected HepG2
compared to the negative control, demon-
strating that PCMV-MT1F plasmid had
been introduced into HepG2 cell and inte-
grated into the genomic DNA.
Detection ofMT1Fprotein in transfected
HepG2 cell
Western blot: MT1Fprotein was shown
for transfected HepG2 compared to the
negative band of the control HepG2
(Figure 1).
Immunocytochemistry: The transfected
HepG2 was positively brown-stained in the
cytoplasmic or nucleus compared to the
negative staining for control. The results
demonstrated that exogenous MTlF gene
introduced into HepG2 expressed high
level ofMT1F protein (Figure 2).
Growth feature oftransfected HepG2
Growth curves: Thetransfected HepG2
cell grew much more slowly in DMEM
medium than the control HepG2 cell
(Figure 3).
Softagargrowth assay: Small and few
colonies were formed slowly in transfected
HepG2 compared to large and numerous
colonies formed quickly in control HepG2.
The colony formation rates were 3.8 per-
cent and 7.4 percent in transfected HepG2
and in control HepG2 respectively (Table
1) which demonstrated that the anchorage
independent growth ability of HepG2
expressing MT1F was reduced.
Tumorigenicity in SCID mice: The
tumorigenicity test showed that the tumors
started to appear on the 25th day after
injection in the six SCID mice injected with
transfected HepG2 on the 13th day in four
SCID mice injected with control HepG2.
The tumors of HepG2 expressing MT1F
grew slowly with an average growth rate
of 30.9 mg/day, and the tumors of control
HepG2 grew fast with an average growth
rate of 70.3 mg/day (Table 2). The results
demonstrated that the tumorigenicity in
SCID mice of MT1F transfected HepG2
was inhibited.60 Lu etal: Metallothionein-1Fgene and hepatocellular carcinoma
Table 1. Soft agar assays in HepG2 cell line
Cell line No.of No. of colonies
CFR
Seeded cell 1 2 3 Mean
HepG2 1000 70 74 78 74±2.4 74 percent
MT1 F-HepG2 1000 36 40 38 38±1.2 38 percentb
bp < .01
Table 2. Tumorigenicity assays in hepG2 cell line.
Cell line Tumorigenicity Growth rate of tumors (mg/day)
Rate 1 2 3 4 5 6 Mean
HepG2 4/4 80.3 75.0 56.3 60.7 - 70.3±5.6
MT1F-HepG2 6/6 21.0 10.3 25.4 56.7 40.0 31.8 30.9±6.9a
ap < .05
Table 3. Expression of MT1F mRNAand proteins in HCC and its para-canceroustissue,
normal tissue n ( percent).
Group n ISH IHC
Normal tissue 20 14 (70.0) 12 (60)
Para-cancerous tissue 60 45 (75.Q)a 40 (66.7)a
Liver cancer 60 10 (16.7)b 6 (10.0)b
ap > .05 Normal tissue vs. para-cancerous tissue.
bp < .01HCC vs. para-cancerous tissue or normal tissue.
MT1F expression among HCC tissue
and its paracancerous tissue, normal
tissue
The expression of MT1F mRNA and
proteininHCCwaslowerthanthatofnormal
tissue or its paracancerous tissue (p < .01,
HCC vs. normal or paracancerous tissue;
p > .05, normal vs. paracancerous tissue)
(Figure 4, Table 3).
DISCUSSION
As we know, the oncogenes and tumor
suppressor genes are involved in the
pathogenesis and development hepatocel-
lular carcinoma [3-5]. Our studies indicate
that MT1F gene as a tumor related-gene is
correlated with the tumor development. It
was reported that MT1F proteins were
decreased and even disappeared in severalLu et al: Metallothionein-1Fgene and hepatocellular carcinoma 61
kinds of cancer tissues; furthermore, the
MT1F mRNA expression was consistent
with the expression level ofMT1F protein
thathadbeen verified in thedown-regulation
ofMTIF occurred at the transcription level
in cancer cells. Southern blot analysis indi-
cated no deletion, no rearrangement or
mutation ofMT1Fon DNAlevel. Theexoge-
nous introduction of MT1F could inhibit
the growth of tumor cells accompanied in
a dose-dependent manner, forexample, the
ability ofanchorage independentgrowthand
tumorigenicity in SCID mice of human
HT1080 fibrosarcoma without original
MT1F was significantly inhibited after the
exogenous introduction of MT1F [6-8]. If
the antisense MT1F was introduced to the
cells, it would inhibit the endogenous
MT1F expression and promote the malig-
nant transformation ofthe cells. In the pre-
sent study, eukaryotic expression vector of
PCMV-MT1F plasmid was introduced into
HepG2 cell line that expressed no MT1F
protein originally with lipofectamine
transfection method. The introduction and
expression of pCMV-MTIF plasmid into
HepG2 cell line was confirmed by G418
selection culture by which colony forma-
tion persisted in next generations and by
PCR amplification of neogene contained
in the vector. Furthermore, the strong
expression ofMT1F protein in transfected
HepG2 was detected by Western blot and
immunocytochemistry, which verified the
success of gene transfection. Growth inhi-
bition ofthe transfected cells shown by the
growth curves, the colony formation rates
in the soft agarand tumorigenicity in SCID
mice demonstrated that exogenous MT1F
gene inhibited the growth ofHepG2.
Recent studies suggest that the mech-
anism of suppression of tumor growth by
MT1F is the MT1F protein has a zinc-fin-
ger domain which regulates the transcrip-
tion ofmany downstream genes by binding
tothe GCrichelementinthepromoterregion
andmodulates genestranscription andvarious
biological effect [5]. MT1F can compete
with transcription activator SPI in binding
to an overlapping consensus binding motif
in the promoter region ofGCE which com-
monly exists in oncogene and tumor sup-
pressor gene and abolishes the function of
SPI, leading to the transcription inhibition
of downstream genes and growth inhibi-
tion of tumor cells [6-8]. In addition the
exogenous MT1F may inhibit the growth
by binding to the GEE ofTGF-P1 and acti-
vating the transcription ofTGF- 1and sub-
sequently activating P21 gene or by down-
regulating Bcl-2 gene to influence the tumor
cells [7, 9, 10]. Some studies indicated that
the activation ofsome oncogenes, e.g., wild
type p53 gene [8], cell apoptosis [9], the
TNF-a [11] andtheconcentration ofcalcium
may be involved in the mechanism of
growth inhibition property ofMT1F. On the
whole, various and complicated mechanisms
may be involved in the suppressive property
ofMT1F to tumor growth [12-14].
MT1F is one of the metallothionein
family which regulates the cellular growth
and differentiation by activating Cyclin DI
to promote the cells from the GO/Glphase
into the G2/M phase [12]. The mechanism
ofdown-expression ofMT1F in cancertis-
sues is not clear up to now. It was hypoth-
esized that the high concentration of
MT1F proteins produced by overstimula-
tion ofMT1F interacted with the promoter
region of EBS and subsequently the gene
transcription was inhibited which was con-
cordant with the present results that showed
strong expression ofMT1F in normal tissue
adjacent to hepatocellular carcinoma and
weekly expression in cancer cells.
Since only down-regulation expres-
sion without gene mutation occurred in
MT1F DNA level, it was different from
some tumor suppressor genes such as p53
[13], p16 [14], and Rb [15] with mutation
gene on DNA level. It is more convenient
to introduce normal exogenous gene into
the tumor cells than torepairmutation gene
in gene therapy [11]. The present study
substantiates that exogenous MT1F as a
target gene has a potential application in
gene therapy ofhepatocellular carcinoma.62 Lu etal: Metallothionein-1F gene and hepatocellular carcinoma
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